Clinical Trials Browser

Phase 1/2 × Lymphoma, T-Cell, Peripheral × 90 days × Clear all

Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell

NCT04390737 2026-01-30

Evaluate the Safety and Clinical Activity of HH2853

Phase 1/2 Recruiting

254 enrolled

LymphoidSarcoma

Lymphoma, Follicular, Sarcoma, Lymphoma, T-Cell, Peripheral

NCT06909877 2026-01-30

Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma

Phase 1/2 Recruiting

100 enrolled

Lymphoid

Recurrence, Lymphoma, T-Cell, Peripheral

NCT02264613 2026-01-13

ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas

Phase 1/2 Completed

142 enrolled 30 charts

Lymphoid

Lymphoma, Lymphoma, T-Cell, Peripheral

NCT04425070 2026-01-05

TOUCH

Phase 1/2 Terminated

56 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral, Lymphoma, Extranodal NK-T-Cell

NCT07093710 2025-12-31

Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma

Phase 1/2 Recruiting

101 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral

Clinical Trials

RELATIVITY-069

Evaluate the Safety and Clinical Activity of HH2853

Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma

ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas

TOUCH

Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma